Authors:
VANDENBORNE BEEM
LANDEWE RBM
THE HSG
RIETVELD JH
ZWINDERMAN AH
BRUYN GAW
BREEDVELD FC
DIJKMANS BAC
Citation: Beem. Vandenborne et al., COMBINATION THERAPY IN RECENT-ONSET RHEUMATOID-ARTHRITIS - A RANDOMIZED DOUBLE-BLIND TRIAL OF THE ADDITION OF LOW-DOSE CYCLOSPORINE TO PATIENTS TREATED WITH LOW-DOSE CHLOROQUINE, Journal of rheumatology, 25(8), 1998, pp. 1493-1498
Authors:
VANDENBORNE BEEM
LANDEWE RBM
THE HSG
BREEDVELD FC
DIJKMANS BAC
Citation: Beem. Vandenborne et al., CYCLOSPORINE-A THERAPY IN RHEUMATOID-ARTHRITIS - ONLY STRICT APPLICATION OF THE GUIDELINES FOR SAFE USE CAN PREVENT IRREVERSIBLE RENAL-FUNCTION LOSS, Arthritis and rheumatism, 41(9), 1998, pp. 729-729
Authors:
VANDENBORNE BEEM
LANDEWE RBM
HOUKES I
SCHILD F
VANDERHEYDEN PCW
HAZES JMW
VANDENBROUCKE JP
ZWINDERMAN AH
THE HSG
BREEDVELD FC
MOENS HJB
KLUIN PM
DIJKMANS BAC
Citation: Beem. Vandenborne et al., NO INCREASED RISK OF MALIGNANCIES AND MORTALITY IN CYCLOSPORINE A-TREATED PATIENTS WITH RHEUMATOID-ARTHRITIS, Arthritis and rheumatism, 41(11), 1998, pp. 1930-1937
Citation: Hsg. The et al., A DOUBLE-BLIND, RANDOMIZED TRIAL TO COMPARE MELOXICAM 15 MG WITH DICLOFENAC 100 MG IN THE TREATMENT OF OSTEOARTHRITIS OF THE KNEE, Osteoarthritis and cartilage, 5(4), 1997, pp. 283-288
Authors:
VANDENBORNE BEEM
LANDEWE RBM
HOUKES I
SCHILD F
VANDERHEYDEN PCW
HAZES JMW
VANDENBROUCKE JP
ZWINDERMAN AH
THE HSG
BREEDVELD FC
MOENS HJB
KLUYN P
DIJKMANS BAC
Citation: Beem. Vandenborne et al., NO INCREASED RISK OF MALIGNANCIES AND MORTALITY IN CYCLOSPORINE-A TREATED RHEUMATOID-ARTHRITIS PATIENTS, Arthritis and rheumatism, 40(9), 1997, pp. 985-985
Citation: Rbm. Landewe et al., THE BENEFIT RISK RATIO OF LOW-DOSE CYCLOSPORINE-A IN RHEUMATOID-ARTHRITIS - REPLY, Journal of rheumatology, 23(2), 1996, pp. 404-405
Authors:
VANDENBORNE BEEM
LANDEWE RBM
THE HSG
BREEDVELD FC
DIJKMANS BAC
Citation: Beem. Vandenborne et al., LOW-DOSE CYCLOSPORINE IN EARLY RHEUMATOID-ARTHRITIS - EFFECTIVE AND SAFE AFTER 2 YEARS OF THERAPY WHEN COMPARED WITH CHLOROQUINE, Scandinavian journal of rheumatology, 25(5), 1996, pp. 307-316
Authors:
VANDENBORNE BEEM
LANDEWE RBM
THE HSG
MATTIE H
BREEDVELD FC
DIJKMANS BAC
Citation: Beem. Vandenborne et al., RELATIVE BIOAVAILABILITY OF A NEW ORAL FORM OF CYCLOSPORINE-A IN PATIENTS WITH RHEUMATOID-ARTHRITIS, British journal of clinical pharmacology, 39(2), 1995, pp. 172-175
Authors:
LANDEWE RBM
THE HSG
VANRIJTHOVEN AWAM
RIETVELD JR
BREEDVELD FC
DIJKMANS BAC
Citation: Rbm. Landewe et al., CYCLOSPORINE IN COMMON CLINICAL-PRACTICE - AN ESTIMATION OF THE BENEFIT RISK RATIO IN PATIENTS WITH RHEUMATOID-ARTHRITIS/, Journal of rheumatology, 21(9), 1994, pp. 1631-1636
Authors:
LANDEWE RBM
THE HSG
VANRIJTHOVEN AWAM
BREEDVELD FC
DIJKMANS BAC
Citation: Rbm. Landewe et al., A RANDOMIZED, DOUBLE-BLIND, 24-WEEK CONTROLLED-STUDY OF LOW-DOSE CYCLOSPORINE VERSUS CHLOROQUINE FOR EARLY RHEUMATOID-ARTHRITIS, Arthritis and rheumatism, 37(5), 1994, pp. 637-643
Authors:
LANDEWE RBM
THE HSG
VANRIJTHOVEN AWAM
BREEDVELD FC
DIJKMANS BAC
Citation: Rbm. Landewe et al., CYCLOSPORINE IN EARLY RHEUMATOID-ARTHRITIS - DELAYED-ONSET OF OPTIMALCLINICAL EFFICACY, Arthritis and rheumatism, 36(9), 1993, pp. 190000215-190000215